US Patent 10,507,186 (methylphenidate coated beads): What the claims cover, how broad they are, and the US patent landscape for delayed/controlled + immediate methylphenidate release
The US patent numbered 10,507,186 claims oral solid “plurality of coated beads” with a three-part methylphenidate release architecture: (1) a first layer with a first methylphenidate amount on/over a granule, (2) an inner controlled-release coating and an outer delayed-release coating stacked over the first layer, and (3) an immediate-release layer on top of the outer delayed-release coating with a second methylphenidate amount. The claims also tie infringement to specific dissolution and fasted in vivo Tmax windows under defined USP paddle testing and simulated gastric/phosphate conditions.
Because the claim set is heavily dependent on (a) layer ordering, (b) quantitative coating amounts, (c) specific polymer families and even specific polymer chemistries in dependent claims, and (d) the dissolution/Tmax performance targets, the practical scope is narrower than broad “multi-layer” language would suggest. The performance parameters operate like functional limitations that can constrain design-around options.
What does US Patent 10,507,186 claim about methylphenidate coated beads and release timing?
Core independent claim concept (Claim 1): a bead that has:
- Granule core
- First layer containing first amount of methylphenidate (or salt)
- Inner controlled-release coating over the first layer
- Outer delayed-release coating over the inner controlled-release coating
- Immediate release layer over the outer delayed-release coating containing second amount of methylphenidate (or salt)
Performance limitations embedded in the claim:
- In vitro dissolution profile using USP paddle method, 100 rpm, 37°C with a defined GI media schedule:
- 0–2 hr: 900 mL simulated gastric fluid
- 2–6 hr: 900 mL phosphate buffer pH 6.0
- ≥7th hour onwards: 900 mL phosphate buffer pH 7.4
- Dissolution targets (“NLT” = not less than) and ranges:
- 1 hr: NLT 15%
- 4 hr: 18–38%
- 8 hr: 35–55%
- 12 hr: 68–98%
- 16 hr: NLT 68%
- Fasted in vivo methylphenidate Tmax windows:
- Tmax0–4 ≈ 1.63 hr
- Tmax8–16 ≈ 12.5 hr
What matters legally: these are not just descriptors. They are part of the claimed bead’s definition. For a challenger, a key question becomes whether an accused product meets the same dissolution acceptance pattern under the same conditions and achieves similar fasted Tmax behavior.
How do Claims 1 and 26 compare in structure?
- Claim 1: explicitly states a first layer on the granule and an immediate release layer on the outer delayed-release coating.
- Claim 26: uses “core” terminology but maps to the same architecture:
- core contains first amount
- inner controlled-release coating + outer delayed-release coating
- immediate release layer containing second amount over the outer delayed-release coating
- same dissolution/Tmax requirements
Practical implication: Claim 26 is a “core/layers” restatement that can capture variations in phrasing while keeping the same structure and performance constraints.
Independent claim coverage of dosage form
- Claims 13 and 14 and 28 extend the bead architecture into an oral solid composition:
- Claim 13: oral solid pharmaceutical composition with the bead population and same dissolution/Tmax.
- Claim 14: specifically capsule comprising the beads.
- Claim 28: oral solid composition comprising claim 26 beads.
Risk for generics/BE entrants: if a product’s bead composition and performance match, dosage-form changes (tablet vs capsule) may not avoid infringement where dependent claims cover capsule, and independent composition claims cover oral solids generally.
How broad are the claim limitations on methylphenidate amounts and layer proportions?
The claim set ties the formulation to quantitative partitioning of methylphenidate between two locations/layers.
Immediate vs first amount split (Claims 6–8; 22–24; 27–29)
- Claim 6: first + second amount provide total methylphenidate in each bead; first amount is 70%–99% of total.
- Claim 7: first amount 78%–82% of total.
- Claim 8: first amount about 80% by weight, second amount about 20% by weight.
Similar proportional limitations appear in:
- Claim 22–24 (composition version)
- Claim 27–29 (beads version with fixed 80/20 split)
Scope effect: fixed ratios in dependent claims can both:
- Create additional infringement hooks for closely matching products, and
- Provide clearer design targets for parties seeking to avoid performance/coverage by shifting the split outside specified ranges.
Coating weight fractions (Claims 3, 19, 29)
- Claim 3 / 19: inner controlled release coating is ~3% to ~16% by weight of each bead.
- Claim 5 / 21: outer delayed release coating is ~3% to ~20% by weight of each bead.
- Claim 29: folds fixed methylphenidate split plus inner and outer coating ranges and immediate release layer presence.
Scope effect: these are meaningful because they constrain how much polymer (inner and outer) is present, not just which polymer chemistry is used.
What polymers and coating chemistries are claimed for the inner controlled-release and outer delayed-release layers?
The claim set uses both:
- Broad polymer class recitations (Claim 2; Claim 18), and
- Specific named polymer types (Claims 10–12 and 15–17 and 16 and 30).
Inner controlled-release coating options
-
Claim 2: inner controlled release coating can be selected from a list including:
- ethylcellulose polymer
- cellulose ether
- polyethylene oxide
- polyvinyl alcohol derivative
- methacrylic acid copolymer
- polyethylene glycol
- polyglycolic acid, polylactic acid
- polycaprolactone
- poly(n-hydroxybutyrate)
- polyamino acid
- poly(amide-enamine)
- polyester
- ethylene-vinyl acetate (EVA)
- PVP
- PAA, PMAA
- mixtures
-
Claim 10: inner controlled release coating comprises ammonio methacrylate copolymer, Type B USP/NF.
-
Claim 12: in combination: inner = ammonio methacrylate copolymer Type B USP/NF; outer = poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1.
Scope effect: Claim 2 is structurally broad, but it still sits inside the independent claim’s dissolution/Tmax/performance limits. If an accused product uses an inner polymer outside the list in Claim 2 but still meets performance, the claim may not cover it unless it falls under another recited category (or performance alone carries infringement, which here it does not because polymer composition is a required element in dependent claims).
Outer delayed-release coating chemistry
- Claim 4: outer delayed release coating is an anionic copolymer based on:
- methyl acrylate, methyl methacrylate, methacrylic acid
- ratio 7:3.1 (as written)
- Claim 11: outer delayed release coating comprises poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1
- Claim 12 and 16 and 17 and 30: use the same outer polymer in the dependent combinations:
- inner = ammonio methacrylate copolymer Type B USP/NF
- outer = poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1
Scope effect: the strongest “tight” coverage sits in dependent claims with the specified outer copolymer ratio and paired inner polymer.
What granule/core types are claimed as acceptable substrates?
Claim 9 lists granule selections:
- sugar sphere
- microcrystalline cellulose granule
- silica granule
- starch granule
- lactose granule
- calcium carbonate granule
- mannitol-polyvinylpyrrolidone granule
Claim 25 and composition counterpart claims restate granule selection in the oral composition context.
Scope effect: these are “allowed core” categories. If an accused product uses a granule type outside the listed set, it may fall outside dependent claim coverage tied to the list, though independent claim coverage (Claim 1) still requires only that a “granule” exists. Practically, the dependent claim granule list can create narrower footholds.
How do the dissolution and fasted Tmax limitations shape enforceable scope?
In vitro dissolution parameters (USP paddle method integration)
The claim explicitly specifies:
- USP paddle method conditions: 100 rpm, 37°C
- Acceptance table: USP <711> Acceptance Table 2
- Stagewise media schedule: simulated gastric fluid, phosphate pH 6.0, phosphate pH 7.4 starting at the 7th hour onwards
- Specific % dissolved targets at 1, 4, 8, 12, 16 hours
Scope effect: this is the main enforceability limiter. A product could have the same layer architecture but fail the dissolution profile under these conditions, potentially weakening or eliminating infringement.
In vivo fasted Tmax windows
- Tmax0–4 ≈ 1.63 hours
- Tmax8–16 ≈ 12.5 hours
Scope effect: these link the formulation to systemic absorption kinetics in the fasted state. For litigation, this increases evidentiary burden because parties must map:
- what “fasted” regimen is used,
- what sampling schedule exists,
- whether Tmax is measured consistently,
- and whether the accused formulation meets the stated windows.
What are the key dependent claims that add precision (and reduce design freedom)?
The dependent claims carve out narrower embodiments:
Polymer precision
- Inner controlled release:
- ethylcellulose/cellulose ether/etc. (broad list) in Claim 2
- ammonio methacrylate copolymer Type B USP/NF in Claim 10
- Outer delayed release:
- anionic copolymer based on methyl acrylate/methyl methacrylate/methacrylic acid with ratio constraints in Claim 4
- specific poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1 in Claim 11
Weight fraction precision
- Inner coating: 3%–16% (Claims 3, 19)
- Outer coating: 3%–20% (Claims 5, 21)
- Fixed methylphenidate split: 80/20 (Claims 8, 24, 27, 29)
Dosage form precision
- Capsule specifically (Claim 14)
Which claim sets most directly map to an infringement theory for a competing methylphenidate bead technology?
Primary theory: independent bead claim + performance
- Claim 1 (or Claim 26 for beads phrasing) is the cleanest template for infringement because it combines:
- layer ordering and presence
- first/second methylphenidate amounts (without fixed 80/20, but with general proportion constraints only in dependent claims)
- mandatory dissolution and fasted Tmax performance
Secondary theory: narrower embodiment claims
A competitor matching the 80/20 split and specific polymer pairs increases likelihood of hitting dependent claims:
- Claim 8 (80/20 methylphenidate split)
- Claim 10 + Claim 11/12 combos (inner ammonio methacrylate Type B + outer 7:3:1 poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid))
Dosage form theories
- If a product is a capsule containing the bead formulation, Claim 14 creates additional claim leverage.
How would a generic or “authorized” entrant design around US 10,507,186 based on claim structure?
Design-around options follow the claim’s enumerated elements:
-
Change layer architecture
If the “immediate release layer coated over outer delayed-release coating” is removed or repositioned, it can evade literal reading. Performance may remain similar but claim requires a specific layering order.
-
Change the polymer chemistries (especially outer delayed)
Dependent claims pin the outer polymer to a specific anionic copolymer composition and ratio. A design that uses a different delayed-release polymer system may avoid dependent claims, though independent claim 1 may still read if “outer delayed release coating” is deemed equivalent to the claimed “anionic copolymer” only where required. In this set, Claim 1 does not enumerate the outer polymer chemistry, but dependent claims do. Litigation typically focuses on the asserted claims, so the patent strategy is claim-dependent.
-
Change coating weight fractions
Dependent claims have ranges for inner and outer coating amounts. Staying outside those ranges can evade those dependent claims.
-
Change the dissolution and/or fasted Tmax performance
Because in vitro and in vivo targets are explicitly recited, moving the dissolution curve outside the specified bands under USP <711> Table 2 and staged media can weaken infringement.
-
Change methylphenidate split
The 70%–99% first amount (Claim 6) and the 78%–82% and 80/20 splits in deeper dependent claims provide quantitative levers. Avoiding exact split ranges can defeat those dependent claims.
Claim-by-claim landscape map (scope ladder within US 10,507,186)
| Claim(s) |
What’s being protected |
Key limiting elements |
Practical scope |
| 1, 26 |
Bead architecture + dissolution + fasted Tmax |
Layer stack order + dissolution targets + Tmax windows |
Broadest within set but constrained by performance |
| 13, 28 |
Oral solid composition with bead architecture + dissolution + Tmax |
Composition includes beads meeting Claim 1/26 limits |
Broad oral solid coverage tied to bead performance |
| 14 |
Capsule dosage form |
Capsule containing beads |
Narrow form factor |
| 2, 18 |
Inner coating polymer alternatives (broad list) |
Must use one of listed inner polymers (in dependent form) |
Broad polymer coverage but only within dependent claim |
| 10, 15, 17, 30 |
Inner ammonio methacrylate copolymer Type B USP/NF |
Specific inner polymer |
Tight embodiment |
| 4, 11, 16, 20, 30 |
Outer delayed-release polymer composition |
Specific anionic copolymer composition/ratio |
Tight embodiment |
| 3, 19 |
Inner coating amount (3%–16%) |
Quantitative coating fraction |
Tight embodiment |
| 5, 21 |
Outer coating amount (3%–20%) |
Quantitative coating fraction |
Tight embodiment |
| 6–8, 22–24, 27–29 |
Methylphenidate split (70%–99%, 78%–82%, 80/20) |
Quantitative distribution between layers/amounts |
Tight embodiment ladder |
| 9, 25 |
Granule substrate types |
Must use listed granule types |
Tight embodiment ladder |
What does this patent imply for the US competitive and litigation risk profile (based on claim design)?
This patent’s strongest competitive threat is to products that already use:
- multi-layer bead constructs with staged immediate + delayed/controlled methylphenidate release, and
- dissolution curves and fasted Tmax matching these targets.
Litigation posture tends to hinge on:
- whether the accused product’s USP <711> dissolution under the exact testing schedule matches,
- whether fasted Tmax matches,
- and whether the formulation uses the same layer ordering and coating architecture.
Because the claim text embeds performance targets, enforcement against near-neighbor formulations may require technical proof rather than only compositional similarity.
Key Takeaways
- US 10,507,186 is centered on a specific triple-layer bead release architecture for methylphenidate: first-layer drug content, inner controlled-release coating, outer delayed-release coating, then an immediate-release layer, all on granule beads.
- Enforceable scope is constrained by explicit functional limitations: the beads must meet a defined USP paddle dissolution profile under staged simulated GI media and provide fasted in vivo Tmax windows (≈1.63 hr for early exposure and ≈12.5 hr for later exposure).
- Dependent claims tighten scope through quantitative constraints: inner coating 3%–16%, outer coating 3%–20%, and methylphenidate split ratios including ~80% first amount and ~20% second amount.
- Polymer-specific dependent claims prioritize combinations with:
- inner: ammonio methacrylate copolymer Type B USP/NF
- outer: poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1
- Design-around strategies track the claim structure: change layer order, shift performance away from the specified dissolution/Tmax windows, move coating amounts outside dependent ranges, or avoid the polymer embodiments in dependent claims.
FAQs
- How does the USP <711> Acceptance Table 2 reference operate in infringement analysis for this patent?
- Does the patent cover both methylphenidate free base and methylphenidate salts equally?
- What role do the fasted-state Tmax windows play compared with the dissolution profile?
- Which dependent claims are most useful for narrowing an accused product’s formulation and process fit?
- What design-around is more likely to succeed: changing outer delayed-release polymer composition or altering the dissolution curve?
References
- US Patent 10,507,186, claims 1–30 (provided claim text).
